Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177 · tracked via the Priya Life Science USA tracker

Sponsor

Tempus AI

Phase

Observational

Started

2022-06-21

Last updated

2025-05-06

Condition(s) studied

Colorectal Cancer

Investigational drug(s) / intervention(s)

Observation

Observation: No intervention

Study summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Known or suspected colorectal adenocarcinoma (Stage I to IVA disease) * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * Willing and able to provide informed consent * Willing to have additional blood samples collected during routine surveillance visits Exclusion Criteria: * Not willing to have additional blood samples collected * Pathology that is not consistent with colorectal adenocarcinoma

Primary outcome measure(s)

Recurrence-Free Survival — 2 years
Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death

Trial sites (20)

Facility	City	Region	Status
Mercy Clinic Oncology - Fort Smith	Fort Smith	Arkansas	Recruiting
MemorialCare	Fountain Valley	California	Recruiting
The Center for Cancer and Blood Disorders	Bethesda	Maryland	Recruiting
Mercy Clinic Oncology and Hematology - Joplin	Joplin	Missouri	Recruiting
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center	Springfield	Missouri	Recruiting
Washington University School of Medicine	St Louis	Missouri	Recruiting
Mercy Clinic Oncology and Hematology - Sindelar Cancer Center	St Louis	Missouri	Recruiting
Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center	St Louis	Missouri	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	Recruiting
Southeastern Medical Oncology Center	Goldsboro	North Carolina	Recruiting
Aultman Hospital	Canton	Ohio	Recruiting
TriHealth Cancer Institute	Cincinnati	Ohio	Recruiting
Ohio State University	Columbus	Ohio	Recruiting
OhioHealth Research Institute	Columbus	Ohio	Recruiting
Toledo Clinic Cancer Center	Toledo	Ohio	Recruiting
Mercy Clinic Oncology and Hematology - Coletta	Oklahoma City	Oklahoma	Recruiting
Cancer Care Associates of York	York	Pennsylvania	Recruiting
Utah Cancer Specialists	Salt Lake City	Utah	Recruiting
University of Washington / Fred Hutchinson Cancer Center	Seattle	Washington	Recruiting
ThedaCare Regional Cancer Center	Appleton	Wisconsin	Recruiting

More Tempus AI trials in the USA

GEMINI-NSCLC: NSCLC Biomarker Study Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies Recruiting

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) Recruiting

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer Recruiting

Tempus Small Cell Lung Cancer Observational Study (Sculptor) Recruiting

Other trials for the same condition

Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors Recruiting

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05234177 on ClinicalTrials.gov ↗ ← All trials in the USA